EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy

Simona Ruxandra Volovat, Dragos Viorel Scripcariu iD, Ingrid Andrada Vasilache, Cati Raluca Stolniceanu, Constantin Volovat iD, Iolanda Georgiana Augustin iD, Cristian Constantin Volovat, Madalina-Raluca Ostafe, Slevoacă-Grigore Andreea-Voichița, Toni Bejusca-Vieriu, Cristian Virgil Lungulescu, Daniel Sur und 1 weitere

International Journal of Molecular Sciences · 18.01.2024 · 25 (2) · 1180

DOI: 10.3390/ijms25021180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.01.2024. Verfasst von Simona Ruxandra Volovat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology-Radiotherapy, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Str., 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 230 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic viruses (OVs) are emerging as potential treatment options for cancer. Natural and genetically engineered viruses exhibit various antitumor mechanisms. OVs act by direct cytolysis, the potentiation of the immune system through antigen release, and the activation of inflammatory responses or indirectly by interference with different types of elements in the tumor microenvironment, modification of energy metabolism in tumor cells, and antiangiogenic action. The action of OVs is pleiotropic, and they show varied interactions with the host and tumor cells. An important impediment in oncolytic virotherapy is the journey of the virus into the tumor cells and the possibility of its binding to different biological and nonbiological vectors. OVs have been demonstrated to eliminate cancer cells that are resistant to standard treatments in many clinical trials for various cancers (melanoma, lung, and hepatic); however, there are several elements of resistance to the action of viruses per se. Therefore, it is necessary to evaluate the combination of OVs with other standard treatment modalities, such as chemotherapy, immunotherapy, targeted therapies, and cellular therapies, to increase the response rate. This review provides a comprehensive update on OVs, their use in oncolytic virotherapy, and the future prospects of this therapy alongside the standard therapies currently used in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyOncolytic VirusesNeoplasmsImmunotherapyCell DeathCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

immune virotherapynanomedicineoncolytic virotherapyviral biotechnologyvirus engineering

Autor:innen und Institutionen

  • Department of Medical Oncology-Radiotherapy, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Str., 700115 Iasi, Romania.
  • Department of Surgery, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Str., 700115 Iasi, Romania.
  • Department of Obstetrics and Gynecology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Department of Biophysics and Medical Physics-Nuclear Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 16 University Str., 700115 Iasi, Romania.
  • Department of Medical Oncology, Al. Trestioreanu Institute of Oncology, 022328 Bucharest, Romania.
  • Department of Radiology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.

ORCID-Profile: Dragos Viorel Scripcariu, Constantin Volovat, Iolanda Georgiana Augustin

Zitieren

APA

Volovat, S. R., Scripcariu, D. V., Vasilache, I. A., Stolniceanu, C. R., Volovat, C., Augustin, I. G., Volovat, C. C., Ostafe, M. R., Andreea-Voichița, S. G., Bejusca-Vieriu, T., Lungulescu, C. V., Sur, D., & Boboc, D. (2024). Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy. International Journal of Molecular Sciences, 25(2), 1180. https://doi.org/10.3390/ijms25021180

Vancouver

Volovat SR, Scripcariu DV, Vasilache IA, Stolniceanu CR, Volovat C, Augustin IG, et al. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy. International Journal of Molecular Sciences. 2024;25(2):1180. doi:10.3390/ijms25021180

BibTeX
@article{Volovat2024,
  author = {Volovat, Simona Ruxandra and Scripcariu, Dragos Viorel and Vasilache, Ingrid Andrada and Stolniceanu, Cati Raluca and Volovat, Constantin and Augustin, Iolanda Georgiana and Volovat, Cristian Constantin and Ostafe, Madalina-Raluca and Andreea-Voichița, Slevoacă-Grigore and Bejusca-Vieriu, Toni and Lungulescu, Cristian Virgil and Sur, Daniel and Boboc, Diana},
  title = {Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {2},
  pages = {1180},
  doi = {10.3390/ijms25021180}
}
Kostenlos starten →